PTC Therapeutics (PTCT) : Traders are bullish on PTC Therapeutics (PTCT) as it has outperformed the S&P 500 by a wide margin of 15.79% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 15.14%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 15.76% in the last 1 week, and is up 13.45% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 11.95% and the 50-Day Moving Average is 21.45%.The 200 Day SMA reached 29.66% PTC Therapeutics, Inc. is up 33.58% in the last 3-month period. Year-to-Date the stock performance stands at -71.88%.
PTC Therapeutics (PTCT) : The highest level PTC Therapeutics (PTCT) is projected to reach is $20 for the short term and the lowest estimate is at $7. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $11.4 and the possibility the share price can swing is $5.03.
Company shares have received an average consensus rating of Hold for the current week PTC Therapeutics (NASDAQ:PTCT): The stock opened at $8.77 and touched an intraday high of $9.2616 on Friday. During the day, the stock corrected to an intraday low of $8.6, however, the bulls stepped in and pushed the price higher to close in the green at $9.11 with a gain of 3.17% for the day. The total traded volume for the day was 1,512,389. The stock had closed at $9.11 in the previous trading session.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).